Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases

PURPOSE: Switch from zoledronic acid (ZA) to denosumab may increase the risk of medication-related osteonecrosis of the jaw (MRONJ) owing to the additive effect of denosumab on the jawbone and residual ZA activities. We evaluated the risk of developing MRONJ in patients who received ZA, denosumab, o...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Chemother Pharmacol
Main Authors: Ikesue, Hiroaki, Doi, Kohei, Morimoto, Mayu, Hirabatake, Masaki, Muroi, Nobuyuki, Yamamoto, Shinsuke, Takenobu, Toshihiko, Hashida, Tohru
Formato: Artigo
Idioma:Inglês
Publicado: Springer Berlin Heidelberg 2021
Assuntos:
Short Communication
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8110486/
https://ncbi.nlm.nih.gov/pubmed/33791853
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-021-04262-w
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares